News & Articles

Detecting lung cancer early with advanced flow cytometry

Our Most Recent News, Events, Press Releases

Latest Information

Latest Updates

bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung

Sales of CyPath® Lung tests continue to accelerate as sales team expands customer base of pulmonology practices SAN ANTONIO, TX (July 9, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today raised its full-year forecast for sales of CyPath® Lung in the Company’s test marketing program by 85% and reported 217% growth in second-quarter sales over first quarter 2024, outpacing the forecast previously reported in May by 75%. CyPath® Lung fulfills the need for a noninvasive test for the early detection of lung cancer and is especially useful for patients whose lung cancer screening or other scan reveals a pulmonary nodule. The lung cancer...
Read More

bioAffinity Technologies News Update

bioAffinity Technologies News Update SAN ANTONIO, Texas (July 3, 2024) – We are pleased to share the latest updates from bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) as we continue to accelerate the commercialization of CyPath® Lung, our...
Full Catalog of Prior Articles, News, Events, and Press Releases

Prior Articles

News & Articles

Precision Pathology laboratory Services

Learn More about CyPath® Lung

The CyPath® Lung Flow Cytometry Test is sold by Precision Pathology Laboratory Services, a bioAffinity Technologies company,  as a Laboratory Developed Test (LDT).

CyPath® Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding.

The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung.

Physician Portal

Patient Portal

How to Order

CyPath® FAQ

Subscribe for News from bioAffinity Technologies